Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Share News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 34.40
Bid: 34.00
Ask: 34.80
Change: -0.60 (-1.71%)
Spread: 0.80 (2.353%)
Open: 35.00
High: 35.00
Low: 34.40
Prev. Close: 35.00
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Premier African plunges on force majeure notice

Mon, 26th Jun 2023 10:06

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

IOG PLC, up 33% at 5.57 pence, 12-month range 3.26p-41.00p. The UK-focused offshore gas developer says it had successfully completed the wireline intervention at the Blythe H2 well, adding that the well has now flowed at a maximum stabilised rate around 42 million standard cubic feet per day, slightly above its original 30 million to 40 million guidance. Production will now be managed up from 20 million feet per day towards the maximum rate to further dewater the pipeline, the company says.

----------

Creo Medical Group PLC, up 9.1% at 36.70 pence, 12-month range 18.34p-91.25p. The medical device company says that the first clinician in Europe has now performed an upper gastrointestinal tract Speedboat Inject case since clearance was gained last week. Speedboat Inject is a multimodal instrument designed for flexible endoscopy. "The result of the procedure was excellent, with the patient leaving hospital shortly after," Creo says. A second doctor is now also trained to use Speedboat Inject for upper GI procedures, the company adds.

----------

AIM - LOSERS

----------

Microsaic Systems PLC, down 51% at 0.011 pence, 12-month range 0.010p-0.014p. The mass spectrometry equipment company says partner DeepVerge owes it GBP1.4 million in unpaid invoices, and it will need to raise additional working capital in the third quarter if these are not paid. Shares in environmental and life sciences company DeepVerge were suspended from trading on AIM on Monday, pending clarification of its financial position. The company had been seeking to sell one or more of its business units in order to raise sufficient funds to allow it to continue to trade. However, DeepVerge failed to do so. As a result, the company said it is unlikely that sufficient funds will be raised in time to allow its business units to continue to trade.

----------

Premier African Minerals Ltd, down 34% at 0.46 pence, 12-month range 0.26p-1.04p. The tungsten producer updates on its offtake and prepayment agreement with Canmax Technologies Co Ltd for the spodumene concentrate produced at the Zulu lithium and tantalum project. Premier African issues a force majeure notice to Canmax due to issues at its plant. A force majeure is a clause that is included in contracts to remove liability for unforeseeable and unavoidable catastrophes that interrupt the expected course of events and prevent participants from fulfilling obligations. As a result, the agreement with Canmax, including those associated with delivery and any consequences associated with it, is suspended. Says no amendment has been signed with Canmax, and adds it will not be signed if they contain terms currently proposed by Canmax. These terms are: the conversion of the pre-payment amount into a convertible debt instrument in the event that Zulu is unable to meet its delivery obligations under the amended agreement or the conversion of a proportionate amount of the equity of Zulu, and the sale to Canmax of all concentrate produced at Zulu at fixed prices with "limited ability for Premier to accommodate cost variations".

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
30 Sep 2021 10:00

Creo Medical losses widen slightly as products progress

(Sharecast News) - Surgical endoscopy technology company Creo Medical reported total first-half sales of £12.9m on Thursday, up from nil sales year-on-year.

Read more
6 Sep 2021 12:38

IN BRIEF: Creo Medical shareholders approve placing and open offer

IN BRIEF: Creo Medical shareholders approve placing and open offer

Read more
16 Aug 2021 18:10

IN BRIEF: Creo Medical to raise GBP5.1 million through open offer

IN BRIEF: Creo Medical to raise GBP5.1 million through open offer

Read more
13 Aug 2021 17:02

IN BRIEF: Creo Medical fundraises to boost growth and develop products

IN BRIEF: Creo Medical fundraises to boost growth and develop products

Read more
12 Aug 2021 19:25

TRADING UPDATES: Corcel buys Wo Wo Gap project; Amiad, UDG leave LSE

TRADING UPDATES: Corcel buys Wo Wo Gap project; Amiad, UDG leave LSE

Read more
16 Jul 2021 14:28

TRADING UPDATES: Luceco tops guidance; Jadestone seals Malaysia buy

TRADING UPDATES: Luceco tops guidance; Jadestone seals Malaysia buy

Read more
16 Jul 2021 11:27

Creo Medical opens new US headquarters as it focuses on market

(Sharecast News) - Surgical endoscopy medical devices company Creo Medical Group has opened its United States headquarters at the Summit in Danbury, Connecticut, it announced on Friday.

Read more
6 Jul 2021 14:57

IN BRIEF: Creo Medical completes GBP4.3 million Chepstow site purchase

IN BRIEF: Creo Medical completes GBP4.3 million Chepstow site purchase

Read more
6 Jul 2021 09:22

Creo Medical buys freehold on head office and adjacent site

(Sharecast News) - Surgical endoscopy device company Creo Medical has completed the freehold purchase of its main headquarters in Chepstow, Creo House, it announced on Tuesday.

Read more
23 Jun 2021 16:09

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
16 Jun 2021 11:56

IN BRIEF: Creo Medical sees first human use of MicroBlate device

IN BRIEF: Creo Medical sees first human use of MicroBlate device

Read more
16 Jun 2021 10:05

Creo upbeat on first in-human use of MicroBlate Fine

(Sharecast News) - Medical device company Creo Medical Group updated the market on its 510(k) US Food and Drug Administration (FDA)-cleared tissue ablation device, 'MicroBlate Fine' on Wednesday, reporting that the device was successfully used for the first in-human, minimally invasive, endoscopic ultrasound (EUS)-guided treatment in a patient with an unresectable pancreatic neuroendocrine tumour.

Read more
14 Jun 2021 14:58

IN BRIEF: Creo Medical buys base and nearby site for GBP4.3 million

IN BRIEF: Creo Medical buys base and nearby site for GBP4.3 million

Read more
14 Jun 2021 09:04

Creo Medical buying freehold of current Chepstow headquarters

(Sharecast News) - Surgical endoscopy-focussed medical device company Creo Medical Group has exchanged contracts to acquire the freehold interest in the current site of its primary headquarters in Chepstow, Creo House, it announced on Monday.

Read more
4 Jun 2021 14:41

Creo Medical revenue jumps in 2020 but loss widens on increased costs

Creo Medical revenue jumps in 2020 but loss widens on increased costs

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.